In the fast-evolving field of synthetic biology, MSJ Biotechnology has reached a new milestone. The company recently completed its Series A+ financing round, securing tens of millions of RMB to fuel its next stage of growth.
Driving innovation in synthetic biology
The fresh capital will allow MSJ Biotechnology to:
- Expand research and development in genetic engineering and synthetic biology
- Advance the clinical translation of recombinant humanized collagen products
- Strengthen its proprietary technology platform
- Establish a new Class III medical device production line in Yixing
Additional follow-on investments are still in progress, with several institutions actively engaged in discussions.
Building on an AI-powered platform
Founded in 2018, MSJ Biotechnology has carved out a strong position in the development of recombinant humanized collagen and related medical devices. Its core strength lies in an AI-driven protein engineering platform, which enables diverse sequence editing, large-scale fermentation, and efficient extraction. This platform provides a stable foundation for producing high-quality recombinant proteins at scale, setting the company apart in the domestic market.
Clinical potential across multiple fields
MSJ’s product pipeline already spans Class II and Class III medical devices, with several candidates currently in clinical trials. The applications are broad, covering plastic surgery, dermatology, general surgery, burn care, and orthopedics. If successful, these products could bring meaningful improvements to multiple areas of clinical practice.
A signal of confidence
The completion of this financing round reflects strong confidence in MSJ Biotechnology’s vision and capabilities. By combining frontier technologies with practical clinical applications, the company is well-positioned to address industry challenges and contribute to the next wave of medical device innovation.